Clinical Trial Update: Topical SGX302 for Mild-to-Moderate Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of topical SGX302 for mild-to-moderate psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• SGX302

Snippet

Sponsor: Soligenix | Conditions: Psoriasis, Plaque Psoriasis | Phase 2 | Status: COMPLETED